Literature DB >> 21481421

Saccadic latency is prolonged in Spinocerebellar Ataxia type 2 and correlates with the frontal-executive dysfunctions.

Roberto Rodríguez-Labrada1, Luis Velázquez-Pérez, Carola Seigfried, Nalia Canales-Ochoa, Georg Auburger, Jacqueline Medrano-Montero, Gilberto Sánchez-Cruz, Raúl Aguilera-Rodríguez, José Laffita-Mesa, Yaimeé Vázquez-Mojena, Marisleydis Verdecia-Ramirez, Maribel Motta, Yudith Quevedo-Batista.   

Abstract

Data on saccadic latency in patients with Spinocerebellar Ataxia 2 (SCA2) are sparse and contradictory. In order to determine whether saccadic latency is definitely prolonged, identify its possible determinants and evaluate it as disease biomarker we assessed the saccadic latency by electronystagmography in 110 SCA2 patients and their paired controls. Mean saccadic latencies were significantly longer in patients when compared to controls for all tested target displacements. Forty-six percent of SCA2 patients had saccadic latencies above the normal range. Reciprobit plots of saccadic latency demonstrated a skewed distribution in the direction of longer latencies for the patients compared to controls. As saccadic latency increased, the velocity and amplitude of saccades significantly decreased in SCA2 subjects but not in controls. Saccadic latency was not influenced by any demographical, clinical or molecular SCA2 variables, but it showed a significant correlation with the performance of the Stroop test, the verbal fluency test and the Wisconsin Card Sorting Test in SCA2 patients. This paper demonstrated that saccadic latency is prolonged in SCA2 patients and it significantly correlates with the performance of frontal-executive functions, thus this parameter could be a useful biomarker to evaluate the efficiency of future therapeutical options on these dysfunctions.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481421     DOI: 10.1016/j.jns.2011.03.033

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Oral zinc sulphate supplementation for six months in SCA2 patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Luis Velázquez-Pérez; Jorge Rodríguez-Chanfrau; Julio Cesar García-Rodríguez; Gilberto Sánchez-Cruz; Raúl Aguilera-Rodríguez; Roberto Rodríguez-Labrada; Julio Cesar Rodríguez-Díaz; Nalia Canales-Ochoa; Dennis Almaguer Gotay; Luis E Almaguer Mederos; José M Laffita Mesa; Marlene Porto-Verdecia; Consuelo González Triana; Noemí Rodríguez Pupo; Idania Hidalgo Batista; Orestes D López-Hernandez; Iverlis Díaz Polanco; Arelis Jayme Novas
Journal:  Neurochem Res       Date:  2011-05-12       Impact factor: 3.996

Review 2.  Spinocerebellar ataxias: prospects and challenges for therapy development.

Authors:  Tetsuo Ashizawa; Gülin Öz; Henry L Paulson
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

3.  Redox Imbalance Associates with Clinical Worsening in Spinocerebellar Ataxia Type 2.

Authors:  Almaguer-Gotay Dennis; Luis E Almaguer-Mederos; Rodríguez-Aguilera Raúl; Rodríguez-Labrada Roberto; Velázquez-Pérez Luis; Cuello-Almarales Dany; González-Zaldívar Yanetza; Vázquez-Mojena Yaimeé; Estupiñán-Domínguez Annelié; Peña-Acosta Arnoy; Torres-Vega Reydenis
Journal:  Oxid Med Cell Longev       Date:  2021-02-19       Impact factor: 6.543

4.  Social and Cultural Elements Associated with Neurocognitive Dysfunctions in Spinocerebellar Ataxia Type 2 Patients.

Authors:  Roberto Emmanuele Mercadillo; Víctor Galvez; Rosalinda Díaz; Lorena Paredes; Javier Velázquez-Moctezuma; Carlos R Hernandez-Castillo; Juan Fernandez-Ruiz
Journal:  Front Psychiatry       Date:  2015-06-10       Impact factor: 4.157

Review 5.  Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches.

Authors:  Luis C Velázquez-Pérez; Roberto Rodríguez-Labrada; Juan Fernandez-Ruiz
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

6.  In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism.

Authors:  Nesli-Ece Sen; Aleksandar Arsovic; David Meierhofer; Susanne Brodesser; Carola Oberschmidt; Júlia Canet-Pons; Zeynep-Ece Kaya; Melanie-Vanessa Halbach; Suzana Gispert; Konrad Sandhoff; Georg Auburger
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.